Alcoholic hepatitis: A comprehensive review of pathogenesis and treatment

World Journal of Gastroenterology

Volumn 20, Issue 20, 2014, Pages 6279-6286

  Chayanupatkul, Maneerat ^a   Liangpunsakul, Suthat ^b,c  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alcoholic hepatitis; Discriminant function; Glasgow alcoholic hepatitis score; Lille model; Liver transplantation; Model for end stage liver disease; Pathogenesis; Treatment

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 8; LACTULOSE; PENTOXIFYLLINE; PROPYLTHIOURACIL; S ADENOSYLMETHIONINE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN B COMPLEX;

ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ARTICLE; ASCITES; CHILD TURCOTTE PUGH SCORE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); ENDOTOXEMIA; ENTERIC FEEDING; GLASGOW ALCOHOLIC HEPATITIS SCORE; HEPATIC ENCEPHALOPATHY; HUMAN; LILLE MODEL; LIVER TRANSPLANTATION; MADDREY DISCRIMINANT FUNCTION; MALNUTRITION; META ANALYSIS (TOPIC); MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PREDICTOR VARIABLE; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SODIUM RESTRICTION; SURVIVAL PREDICTION; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; TREATMENT OUTCOME; WERNICKE ENCEPHALOPATHY; ALCOHOLISM; END STAGE LIVER DISEASE; HEPATITIS, ALCOHOLIC; INFLAMMATION; INNATE IMMUNITY; PATHOPHYSIOLOGY; PROCEDURES;

ACETYLCYSTEINE; ADRENAL CORTEX HORMONES; ALCOHOLISM; END STAGE LIVER DISEASE; ENTERAL NUTRITION; HEPATITIS, ALCOHOLIC; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIVER TRANSPLANTATION; PENTOXIFYLLINE; PROPYLTHIOURACIL; S-ADENOSYLMETHIONINE; TREATMENT OUTCOME;

EID: 84901486232     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i20.6279     Document Type: Article

References (94)

1. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011; 45: 714-719. [PMID: 21085006 DOI: 10.1097/MCG.0b013e3181fdef1d]
2. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010; 51: 307-328. [PMID: 20034030 DOI: 10.1002/hep.23258]
3. Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981; 10: 417-441. [PMID: 7018751]
4. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585. [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
5. Bautista AP. Impact of alcohol on the ability of Kupffer cells to produce chemokines and its role in alcoholic liver disease. J Gastroenterol Hepatol 2000; 15: 349-356. [PMID: 10824877 DOI: 10.1046/j.1440-1746.2000.02174.x]
6. Laso FJ, Lapeña P, Madruga JI, San Miguel JF, Orfao A, Iglesias MC, Alvarez-Mon M. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol Clin Exp Res 1997; 21: 1226-1231. [PMID: 9347083]
7. Bird G. Interleukin-8 in alcoholic liver disease. Acta Gastroenterol Belg 1994; 57: 255-259. [PMID: 7810274]
8. Spahr L, Giostra E, Frossard JL, Bresson-Hadni S, RubbiaBrandt L, Hadengue A. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol 2004; 41: 229-234. [PMID: 15288471 DOI: 10.1016/j.jhep.2004.04.028]
9. Stewart SF, Vidali M, Day CP, Albano E, Jones DE. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology 2004; 39: 197-203. [PMID: 14752838 DOI: 10.1002/hep.20021]
10. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001; 7: 408-413. [PMID: 11530336 DOI: 10.1016/ S1471-4914(01)02096-2]
11. McClain CJ, Shedlofsky S, Barve S, Hill DB. Cytokines and alcoholic liver disease. Alcohol Health Res World 1997; 21: 317-320. [PMID: 15706742]
12. Hansen J, Cherwitz DL, Allen JI. The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. Hepatology 1994; 20: 461-474. [PMID: 8045508 DOI: 10.1002/hep.1840200228]
13. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, Schiff ER, McClain CJ, Marsano LS, Allen JI. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17: 564-576. [PMID: 8477961 DOI: S0270913993000771]
14. Han SH, Rice S, Cohen SM, Reynolds TB, Fong TL. Duplex Doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J Clin Gastroenterol 2002; 34: 573-577. [PMID: 11960073 DOI: 10.1097/00004836-200205000-00019]
15. Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24: 835-838. [PMID: 520102 DOI: 10.1007/BF01324898]
16. Arteel G, Marsano L, Mendez C, Bentley F, McClain CJ. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 2003; 17: 625-647. [PMID: 12828959 DOI: 10.1016/ S1521-6918(03)00053-2]
17. Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jakobsen J, Dørup I. Magnesium supplementation and muscle function in patients with alcoholic liver disease: a randomized, placebo-controlled trial. Scand J Gastroenterol 2005; 40: 972-979. [PMID: 16173138 DOI: 10.1080/00365520510012361]
18. Rodríguez-Moreno F, González-Reimers E, Santolaria-Fernández F, Galindo-Martín L, Hernandez-Torres O, Batista-López N, Molina-Perez M. Zinc, copper, manganese, and iron in chronic alcoholic liver disease. Alcohol 1997; 14: 39-44. [PMID: 9014022 DOI: 10.1016/S0741-8329(96)00103-6]
19. Yersin B, Nicolet JF, Dercrey H, Burnier M, van Melle G, Pécoud A. Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med 1995; 155: 1907-1911. [PMID: 7677558 DOI: 10.1001/archinte.1995.00430170103013]
20. Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res 1991; 15: 45-66. [PMID: 2059245 DOI: 10.1111/ j.1530-0277.1991.tb00518.x]
21. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430-435. [PMID: 6724511 DOI: 10.1002/ hep.1840040313]
22. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199. [PMID: 352788]
23. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-1354. [PMID: 17518367 DOI: 10.1002/hep.21607]
24. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2. [PMID: 11835693 DOI: 10.1186/1471-230X-2-2]
25. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-1179. [PMID: 16009691 DOI: 10.1136/ gut.2004.050781]
26. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903. [PMID: 15158328 DOI: 10.1016/ j.jhep.2004.02.010]
27. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-706. [PMID: 15826720 DOI: 10.1016/j.jhep.2004.12.022]
28. Jeong JY, Sohn JH, Son BK, Paik CH, Kim SH, Han DS, Jeon YC, Lee MH, Lee DH, Kee CS. [Comparison of model for end-stage liver disease score with discriminant function and child-Turcotte-Pugh scores for predicting short-term mortality in Korean patients with alcoholic hepatitis]. Korean J Gastroenterol 2007; 49: 93-99. [PMID: 17322788]
29. Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-690. [PMID: 2648927 DOI: 10.7326/0003-4819-110-9-685]
30. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-487. [PMID: 11943418 DOI: 10.1016/ S0168-8278(01)00289-6]
31. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2022-2036. [PMID: 9820369 DOI: 10.1111/j.1572-0241.1998.00587.x]
32. Kulkarni K, Tran T, Medrano M, Yoffe B, Goodgame R. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004; 38: 453-459. [PMID: 15100527 DOI: 10.1097/00004836-200405000-00012]
33. Louvet A, Wartel F, O'Grady J. A response guided therapy for a better management of patients with severe alcoholic hepatitis treated with corticosteroid. Hepatology 2010; 524 Suppl: 1109A
34. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470. [PMID: 11172350 DOI: 10.1053/jhep.2001.22172]
35. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-358. [PMID: 15660383 DOI: 10.1002/ hep.20503]
36. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-2769. [PMID: 19553649 DOI: 10.1056/NEJMra0805786]
37. Barr SI. Applications of Dietary Reference Intakes in dietary assessment and planning. Appl Physiol Nutr Metab 2006; 31: 66-73. [PMID: 16604145 DOI: 10.1139/h05-020]
38. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-1795. [PMID: 12724485 DOI: 10.1056/NEJMra020617]
39. Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004; 24: 233-247. [PMID: 15349802 DOI: 10.1055/s-2004-832937]
40. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178. [PMID: 18363896 DOI: 10.1111/ j.1365-2036.2008.03685.x]
41. Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977; 22: 477-484. [PMID: 326034 DOI: 10.1007/ BF01072499]
42. Campra JL, Hamlin EM, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973; 79: 625-631. [PMID: 4751740 DOI: 10.7326/0003-4819-79-5-62 5]
43. Depew W, Boyer T, Omata M, Redeker A, Reynolds T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78: 524-529. [PMID: 6985881]
44. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Weesner R, Zetterman R. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311: 1464-1470. [PMID: 6390194 DOI: 10.1056/NEJM198412063112302]
45. Porter HP, Simon FR, Pope CE, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971; 284: 1350-1355. [PMID: 4930603 DOI: 10.1056/NEJM197106172842404]
46. Shumaker JB, Resnick RH, Galambos JT, Makopour H, Iber FL. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978; 69: 443-449. [PMID: 356593]
47. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23: 75-79. [PMID: 7035299]
48. Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-512. [PMID: 1531090 DOI: 10.1056/ NEJM199202203260802]
49. Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971; 74: 311-321. [PMID: 4928161 DOI: 10.7326/0003-4819-74-3-311]
50. Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978; 74: 169-173. [PMID: 340319]
51. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-118. [PMID: 7672658]
52. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260. [PMID: 20940288 DOI: 10.1136/gut.2010.224097]
53. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113: 299-307. [PMID: 2142869]
54. Sougioultzis S, Dalakas E, Hayes PC, Plevris JN. Alcoholic hepatitis: from pathogenesis to treatment. Curr Med Res Opin 2005; 21: 1337-1346. [PMID: 16197651 DOI: 10.1185/030079905X56493]
55. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Kunkel SL. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-1236. [PMID: 2460096]
56. Morgan TR, McClain CJ. Pentoxifylline and alcoholic hepatitis. Gastroenterology 2000; 119: 1787-1791. [PMID: 11113103]
57. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648. [PMID: 11113085]
58. Sidhu SS, Goyal O, Singla M, Bhatia KL, Chhina RS, Sood A. Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. J Assoc Physicians India 2012; 60: 20-22. [PMID: 23029716]
59. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15: 1613-1619. [PMID: 19340904]
60. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013; 310: 1033-1041. [PMID: 24026598 DOI: 10.1001/jama.2013.276300]
61. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thévenot T, Deltenre P, Canva V, Plane C, Mathurin P. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48: 465-470. [PMID: 18164508 DOI: 10.1016/j.jhep.2007.10.010]
62. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; (4): CD007339. [PMID: 19821406 DOI: 10.1002/14651858. CD007339.pub2]
63. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-854. [PMID: 23489011 DOI: 10.1111/apt.12279]
64. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol 2014; 12: 555-564; quiz e31-32. [PMID: 23811249 DOI: 10.1016/j.cgh.2013.06.013]
65. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397. [PMID: 15122768 DOI: 10.1002/hep.20206]
66. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-425. [PMID: 12663232]
67. Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009; 50: 584-591. [PMID: 19155081 DOI: 10.1016/j.jhep.2008.10.024]
68. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960. [PMID: 18848937 DOI: 10.1053/j.gastro.2008.08.057]
69. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76: 211-222. [PMID: 6421159]
70. Schenker S, Halff GA. Nutritional therapy in alcoholic liver disease. Semin Liver Dis 1993; 13: 196-209. [PMID: 8337604]
71. Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004; 28: 173-181. [PMID: 14745316]
72. Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombraña JL, Parés A, Papo M, Planas R, Gassull MA. Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36-42. [PMID: 10869286 DOI: 10.1053/jhep.2000.8627]
73. Moreno C, Langlet P, Hittelet A, Lasser L, Degré D, Evrard S, Colle I, Lemmers A, Devière J, Le Moine O. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 2010; 53: 1117-1122. [PMID: 20801542 DOI: 10.1016/j.jhep.2010.05.030]
74. Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47: 277-283. [PMID: 17532088 DOI: 10.1016/j.jhep.2007.03.027]
75. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. J Hepatol 2006; 44: 784-790. [PMID: 16469404 DOI: 10.1016/j.jhep.2005.11.039]
76. Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365: 1781-1789. [PMID: 22070475 DOI: 10.1056/NEJMoa1101214]
77. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002; 97: 1674-1681. [PMID: 12135017 DOI: 10.1002/14651858.CD003045.pub2]
78. Israel Y, Kalant H, Orrego H, Khanna JM, Videla L, Phillips JM. Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci USA 1975; 72: 1137-1141. [PMID: 1055371]
79. Iturriaga H, Ugarte G, Israel Y. Hepatic vein oxygenation, liver blood flow, and the rate of ethanol metabolism in recently abstinent alcoholic patients. Eur J Clin Invest 1980; 10: 211-218. [PMID: 6783417]
80. Lee E, Miki Y, Katsura H, Kariya K. Mechanism of inactivation of myeloperoxidase by propylthiouracil. Biochem Pharmacol 1990; 39: 1467-1471. [PMID: 2159305]
81. Orrego H, Kalant H, Israel Y, Blake J, Medline A, Rankin JG, Armstrong A, Kapur B. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 1979; 76: 105-115. [PMID: 758131]
82. Hallé P, Paré P, Kaptein E, Kanel G, Redeker AG, Reynolds TB. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982; 82: 925-931. [PMID: 7037524]
83. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2005; (4): CD002800. [PMID: 16235302]
84. Fede G, Germani G, Gluud C, Gurusamy KS, Burroughs AK. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2011; (6): CD002800. [PMID: 21678335 DOI: 10.1002/14651858.CD002800.pub3]
85. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-1089. [PMID: 10406187]
86. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2001; (4): CD002235. [PMID: 11687153 DOI: 10.1002/14651858.CD002235.pub2]
87. Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704]
88. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628-637. [PMID: 9404965]
89. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvot FR, Duclos-Vallée JC. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-1800. [PMID: 22070476 DOI: 10.1056/NEJMoa1105703]
90. Chung T, Martin CS, Winters KC. Diagnosis, course, and assessment of alcohol abuse and dependence in adolescents. Recent Dev Alcohol 2005; 17: 5-27. [PMID: 15789857]
91. Brown SA, Anderson KG, Ramo DE, Tomlinson KL. Treatment of adolescent alcohol-related problems. A translational perspective. Recent Dev Alcohol 2005; 17: 327-348. [PMID: 15789874]
92. Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl 2005; (15): 148-156; discussion 140. [PMID: 16223066]
93. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-1625. [PMID: 15811981 DOI: 10.1001/jama.293.13.1617]
94. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-1922. [PMID: 18068515 DOI: 10.1016/S0140-673607)61814-5]